Clinical trial
Use Of SB-705498 In The Acute Treatment Of Migraine
NCT00269022 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00269022 |
|---|---|
| Title | Use Of SB-705498 In The Acute Treatment Of Migraine |
| Official title | A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Migraine, Acute |
| Intervention type | Drug |
| Interventions | SB-705498 |
| Enrollment | 70 |
| Start date | Jan 1, 2006 |
| First posted | Dec 23, 2005 |
| Last update posted | May 18, 2009 |
| Countries | Australia, Canada, Netherlands, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: